MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

Home » Caliper closes Xenogen Biosciences small animal deal, lowers Q4 guidance

Caliper closes Xenogen Biosciences small animal deal, lowers Q4 guidance

By

Caliper Life Sciences Inc. (NSDQ:CALP) closed an $11 million deal to sell Xenogen Biosciences Corp. to Taconic Farms Inc. and lowered its fourth-quarter guidance as a result.

The Hopkinton, Mass.-based lab equipment and services provider acquired XenBio subsidiary, which supplies genetically altered small animals to drug developers, when it bought Xenogen Corp. in 2006. About 90 percent of the business involves selling genetically engineered rodents called “light producing transgenic animals,” which have been modified to produce substances that fluoresce when examined using special imaging equipment, according to Caliper’s website.

Caliper makes the equipment designed to highlight these “optical reporters,” such as luciferase, and the deal includes a distribution agreement between the company and Taconic. The Hudson, N.Y.-based small research animal supplier will distribute the Caliper light-producing transgenic animals and have the non-exclusive right to “perform imaging services under Caliper’s extensive patent estate in this field,” according to a press release. Taconic will also be able to develop new LPTA lines compatible with the Ivis imaging system.

Caliper president and CEO Kevin Hrusovsky said the deal help his company consolidate and focus on one of its core businesses, optical imaging. Caliper will get about $9 million in cash up front during the fourth quarter, plus future payments from the distribution and licensing deal.

The company downgraded its sales forecast for the fourth quarter as a result of the deal, to $33 million to $35 million. Its previous guidance was for Q4 revenues of $34.5 million to $36.5 million.

Caliper narrowed its net loss by more than 37 percent during the third quarter, despite a top-line slide of nearly 6 percent, with revenues of $32.2 million during the three months ended Sept. 30 (compared with $34 million during the same period last year). Net losses for the quarter were $3.4 million, down 37.4 percent compared with $5.4 million during the third quarter of 2008.

In case you missed it

RSS From Medical Design & Outsourcing

  • FDA will review fewer COVID-19 test EUA submissions
    The FDA is pushing COVID-19 test developers away from emergency use authorization (EUA) submissions in favor of more traditional pathways, the agency said today. The FDA said it intends to review “only a small subset” of new EUA submissions, encouraging test makers to seek regulatory approval through de novo classification or 510(k) clearance pre-market review… […]
  • Integra plans to shrink the C-suite after executive’s exit
    Integra Lifesciences (Nasdaq: IART) will eliminate the position of chief operating officer next week — though the office is already empty. Former COO Glenn Coleman’s last day at Integra was Friday, according to a separation agreement filed with the Securities and Exchange Commission that same day. Coleman was scheduled to start as the new EVP and… […]
  • Steris plans to build a new medical device testing facility
    Steris (NYSE: STE) plans to build a new packaging and microbiological testing facility for medical devices in Leipzig, Germany. The facility will offer packaging testing services such as accelerated and real-time aging, transportation and integrity testing. The new location will also offer microbiological testing in collaboration with the medical device manufacturer and sterilizer’s laboratory in… […]
  • 10 medical device startups you need to know
    Some of the most interesting medical device startups of 2022 are advancing a wide range of innovative medtech: robotics, catheter-delivered brain-computer interfaces and more. The editors here at Medical Design & Outsourcing and MassDevice are writing about medical device startups all the time. But there are some device companies starting out that have technologies that… […]
  • Steris stock downgraded as analysts expect lawyers to seek more ethylene oxide lawsuits
    Steris (NYSE: STE) stock was downgraded today by Needham from buy to hold following the $363 million jury verdict against its primary competitor, Sterigenics, over ethylene oxide (EtO) emissions. Needham analysts said they expect attorneys to target communities near EtO facilities with ads to find people willing to file more lawsuits against sterilization plant operators… […]
  • Researchers develop at-home device to track Parkinson’s progression
    Researchers at MIT and the University of Rochester Medical Center have developed a device to monitor a Parkinson’s patient at home. Collecting data at home could help provide a less subjective measurement than evaluations at the doctor’s office, which can be affected by outside factors. The technology could also help pharmaceutical and biotech companies developing… […]
  • Micro Mold renovates for new 5-axis milling center
    Precision mold maker Micro Mold has renovated in Erie, Pennsylvania, to make room for its new Yasda YMC650 high-speed 5-axis milling center and 3R Workpartner automation cell. The new equipment will be used for electrode manufacturing and finishing hard mill applications. The milling machine is accurate to 1 micron for high-volume, ultra-precision tooling work, the… […]
  • September 2022 Issue: The Medtech Big 100 is bigger than ever
    Medtech sales reach a record high as R&D spend and employee counts climb Supply Chain EVP Greg Smith sees fewer suppliers in Medtronic’s future Autotransfusion device maker ships units to Ukraine How IP protection is enabling robotic surgery innovation Connected device design for the real world: Managing the development process FDA details plans to expand… […]
  • How NeuroOne and Zimmer Biomet will partner on robotic brain surgery
    NeuroOne (NASDAQ: NMTC) is preparing its depth electrode technology for commercialization through Zimmer Biomet (NYSE: ZBH) while waiting for FDA feedback on its latest submission. NeuroOne’s Evo stereoelectroencephalography (sEEG) device won FDA 510(k) clearance in September 2021 for recording, monitoring, and stimulation of electrical signals at the subsurface level of the brain. That clearance was… […]
  • Trelleborg to show off advanced polymer tech at MD&M Minneapolis
    Trelleborg Healthcare & Medical will exhibit advanced polymer technologies for medical applications at MD&M Minneapolis, which runs Nov. 2–3, 2022. The Sweden-based engineering polymer giant, which has operations in 50 companies, has newly acquired, advanced capabilities in thermoplastic injection molding. The new injection molding capabilities come from its purchase of Menomonie, Wisconsin–based EirMed earlier this… […]
  • Millstone Medical Outsourcing expands cleanroom facility
    Millstone Medical Outsourcing said today that it has broken ground on a 5,000-square-foot cleanroom facility expansion at its Fall River, Massachusetts headquarters. The project is Millstone’s third cleanroom expansion. The additional Class 10,000/ISO7-rated cleanroom space is for medical device packaging operations. It will bring the company’s total cleanroom footprint to 20,000 square feet. Responding to… […]

Leave a Reply